☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
bergenbio
BerGenBio Reports the Data from P-Ib/IIa (BGBC016) Clinical Evaluation of Bemcentinib as 1L Treatment of NSCLC
October 7, 2024
BerGenBio and Tempus Collaborate to Advance the Development of STK11m to Treat NSCLC
August 22, 2024
PharmaShots Weekly Snapshots (March 06 - 10, 2023)
March 10, 2023
BerGenBio Reports P-II Trial Results of BGB324 (bemcentinib) as 2L Treatment of Non-Small Cell Lung Cancer
February 16, 2023
Bergenbio Reports Results of Bemcentinib in P-II (ACCORD2) Study for the Treatment of COVID-19
April 26, 2022
PharmaShots Weekly Snapshot (October 21-25, 2019)
October 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.